disclaimer: tweets are my own opinions & should not be seen as any investment advice Corporate-finance & stocks (sp) are associated with risks & uncertainties
Joined June 2014
- Tweets1K
- Following34
- Followers946
- Likes4.5K
Pinned Tweet
$ABCL AbCellera – a true diamond
I love technical analysis.
I’ve spent years mastering indicators, reading charts, recognizing patterns. But no matter how precise it is, technicals will always come second to instinct.
When I first found AbCellera ($ABCL), I was just curious. I didn’t invest a cent—not until I started digging deeper.
I discovered Carl Hansen, the CEO. A brilliant scientist with unmatched passion. He once spent a week in Dr. James’ lab and completed more experiments than their best student would in a year, creating Fluidigm’s first commercial product.
Carl isn’t just running a company—he’s building a legacy.
AbCellera’s silence on social media frustrated me at first. But after a year of watching, I get it. They don’t talk. They execute.
I kept digging.
They helped DARPA deliver a COVID antibody, partnered with Lilly, secured Canadian government funding, built state-of-the-art facilities, amassed huge cash reserves, and filed unique microfluidics patents (recently defended successfully in court). Their GMP manufacturing site goes live this year. How many biotechs can say the same?
Then I looked at the chart. From $60 to $2. The market punished them for lack of revenue, not realizing they were quietly transforming into a company that could rival Big Pharma.
As an entrepreneur, I get it. My first store thrived, then struggled. I reinvested, expanded, and now I’m in a place I never imagined.
AbCellera is doing the same. They’ve been underestimated because few realized how much they were restructuring to achieve 100x what they did when shares were $40.
Insiders buying at $2.16 and $3.24 shows confidence from those who know more than any of us. Institutions went from 40% to 60% ownership in months.
I’m no institution. I’m just a retail investor who went all-in on Carl Hansen.
And yes, I once dreamt of Carl. At $2 he smiled and said, “Great things are coming.”
That’s the Carl I feel in my gut. My all-in bet will pay off.
AbCellera isn’t a meme stock. It’s not a penny stock.
It’s a biotech titan in the making.
I’m already smiling at the thought of $20… $30… $40.
rss.nicho retweeted
$ABCL Had a great time discussing AbCellera with @em013L today - Almost 3 hours long. We discuss a lot of things including my take on the thesis, liquidity, cash flow exercise, risk/reward, and more. Hope you enjoy!
This Early Palantir Investor Is Betting Big On AbCellera! LIVE! teapawt.net/i/broadcasts/1mrGmBomq…
🔥 THE SQUEEZE IS BACK. YOU'RE READY? 🔥
$ABCL is not just climbing, it's charging.
📈 Closed yesterday at $4.24.
📊 After-hours? Blasted through $5.10.
🚀 Premarket volume already high, printing green like it’s 2021.
💥 Options OI off the charts. Gamma ramp between $5 and $8 is loaded.
🛑 Shorts trapped again, no escape this time.
🏦 Institutional volume spiked 4M in the last hour pre-call. You think that’s a coincidence?
We’ve got the fundamentals.
We’ve got the setup.
We’ve got the volume.
And now we’ve got the FOMO ignition.
The shorts had 8 months to run.
They didn’t.
Now it’s our turn.
📍 Price target? Ask the market.
💣 Catalyst? Already dropped.
THE SQUEEZE IS BACK.
Are you?
#ABCL #ShortSqueeze #WallStreetBets #GammaRamp #NotLeaving #ToTheMoon
$ABCL
10$ coming soon 😎
Obviously not financial advice.
I'm surprised. $ABCL is the next biotech giant, the most promising, the best positioned. And you're unaware of this mega discount to $4.30? This might be your last chance to buy it at a discount. If you wait until it becomes obvious to everyone, you'll buy it at its true value, not at a discount.
Like those who didn't buy $PLTR at $7 but got it at $120.
Alright. NOW I’m hyped.
These $ABCL calls expire in one week.
And what do we see?
Nearly 5,000 OI at $5
2,500 at $6
Close to 3,000 at $7
Even $8–$10 showing signs of life
After tonight’s explosive after-hours over $5, we’ve officially entered the danger zone, for the shorts, not for us. 😈😈😈
Why?
Because if $5 breaks with volume, market makers must start hedging these strikes.
That means buying real shares on the open market → triggering gamma pressure → triggering short covers → and you know what happens next.
We've got the fuel:
✔️ Earnings beat
✔️ Bullish call
✔️ First +AH close in three quarters
✔️ Short interest still >17% 35M shares.
✔️ And now? A fully stacked options chain waiting to ignite. AHAHAHAHAHA
So yeah...
Let’s. Freakin’. Enjoy. This. Ride. 🚀
#ABCL #ShortSqueeze #GammaSqueeze #Biotech #OptionsFlow
rss.nicho retweeted
$ABCL CFO reiterated that their current cash position can fund three more years of R&D—even with an expanding pipeline of drug programs.
To me, that signals growing operational efficiency: the ability to process more data and support more programs without needing to dramatically increase spending.
In a business where time to market is extremely long and uncertainty is high, expanding the number of parallel programs is critical. More verticals and built-in backups significantly raise the odds of success.
$ABCL
Guys, I can’t tell you how happy I am, these earnings truly reflect the massive potential and the strategic vision of AbCellera’s board.
They didn’t say a word until today.
Now we’re looking at a massive cash position, a new internally developed pipeline candidate, 102 partner programs initiated, 18 molecules in the clinic, two of which are proprietary and already in trials.
The GMP facility is up and running, revenue and EPS beat expectations.
And the call hasn’t even started yet, who knows what else might come out.
I repeat, I’m just so happy.
Now more than ever, $4–$5 is way too little for this giant.
$ABCL deserve 10$ tomorrow.
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
ow.ly/XtfB50WBHnz
$ABCL It's all set. One spark and we ignite.
🔻 Short Interest: 35.7M shares
📉 Short % Float: 17.65%
That's a ticking bomb.
Now zoom out and look at the options chain expiring Aug 15:
Over 5,000 OI at $5, nearly 3,000 at $6, and still heavy OI building up to $8.
The stock just needs one bullish catalyst and everything’s in place:
→ Shorts will cover
→ Gamma squeeze will accelerate
→ We go vertical
Earnings in 1 days.
Options expiry in 9 days.
Pressure’s building. Timing is perfect.
They’ve shorted it into a corner and now there’s no way out.
#ABCL #ShortSqueeze #GammaSqueeze #Biotech #OptionsFlow
